BUZZ - Oppenheimer bullish on Veru: "Came for lean body mass, stayed for muscle function"

October 14 - ** Oppenheimer Securities gives drug developer Veru stock VERU.O an “outperform” rating, with a target price of $24, citing that the stock still has considerable upside potential from current levels.

** The stock’s latest closing price was $2.19, up 2.3% year-to-date

** The brokerage stated it has strong confidence in Veru’s experimental oral drug enobosarm, and expects that in the upcoming quarter’s interim analysis it will demonstrate a significant effect in maintaining lean body mass, as well as greater fat reduction compared to using semaglutide alone.

** The brokerage said that such results would reduce the risk to Q4 2027 revenue and could make enobosarm an ideal choice for patients most at risk of GLP-1-related muscle loss.

** TD Cowen analysts previously noted that weight-loss therapies aimed at helping patients maintain muscle while losing weight could (link) generate over $30 billion in sales by 2035.

** Oppenheimer pointed out that if upcoming trial results show a sustained increase in lean muscle mass and sustained decrease in fat mass, this would provide evidence for the long-term benefits of using enobosarm in combination with GLP-1 weight-loss drugs.

(To assist non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely as a convenience to readers. Reuters accepts no responsibility for any damage or loss incurred due to the use of automated translation.)